Clinical Outcomes with Multikinase Inhibitors after Progression on First-Line Atezolizumab plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma: A Multinational Multicenter Retrospective Study

Yoo, C; Kim, JH; Ryu, MH; Park, SR; Lee, D; Kim, KM; Shim, JH; Lim, YS; Lee, HC; Lee, J; Tai, DV; Chan, SL; Ryoo, BY

Ryoo, BY (corresponding author), Univ Ulsan, Asan Med Ctr, Dept Oncol, Coll Med, 88,Olymp Ro 43 Gil, Seoul 05505, South Korea.; Chan, SL (corresponding author), Prince Wales Hosp, Dept Clin Oncol, Shatin, 30-32 Ngan Shing St, Hong Kong, Peoples R China.

LIVER CANCER, ; ():

Abstract

Introduction: Atezolizumab-bevacizumab is the new standard of care for first-line treatment of advanced hepatocellular carcinoma (HCC). However, the o......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索